论文部分内容阅读
目的:分析拉米夫定与阿德福韦酯联用治疗慢性病毒性肝炎患者的临床疗效。方法:选取2012年9月—2013年9月间确诊收治的慢性病毒性肝炎患者104例,将其分为治疗组和对照组,各52例;治疗组患者给予拉米夫定与阿德福韦酯治疗,对照组患者给予单用恩替卡韦治疗,评价两组患者治疗48周后肝功能情况变化及临床疗效。结果:治疗组患者治疗后ALT(38.5±4.9)U/L,TBIL(15.8±6.8)μmol/L和AST(33.9±3.7)U/L值均低于对照组为ALT(92.4±55.7)U/L,TBIL(29.7±7.1)μmol/L和AST(80.4±25.6)U/L(P<0.05);治疗后治疗组患者总有效率为92.31%,显著高于对照组为76.92%(P<0.05)。结论:拉米夫定与阿德福韦酯联用治疗慢性病毒性肝炎患者优于单用恩替卡韦治疗。
Objective: To analyze the clinical efficacy of lamivudine combined with adefovir dipivoxil in the treatment of patients with chronic viral hepatitis. Methods: A total of 104 patients with chronic viral hepatitis diagnosed from September 2012 to September 2013 were selected and divided into treatment group and control group, with 52 patients in each group. Patients in the treatment group were given lamivudine and adefovir Estrogen treatment, control group patients given entecavir alone treatment, evaluation of two groups of patients after 48 weeks of treatment of liver function changes and clinical efficacy. Results: After treatment, the ALT (38.5 ± 4.9) U / L, TBIL (15.8 ± 6.8) μmol / L and AST (33.9 ± 3.7) U / L in the treatment group were significantly lower than those in the control group (92.4 ± 55.7 U (P <0.05). After treatment, the total effective rate of the treatment group was 92.31%, which was significantly higher than that of the control group (76.92%, P <0.05). Conclusion: Lamivudine combined with adefovir dipivoxil is superior to entecavir alone in the treatment of chronic viral hepatitis.